Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19352045 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | October 2025 | December 2025 | Allow | 2 | 0 | 0 | No | No |
| 19256050 | HYDRATE OF VEGFR INHIBITOR, CRYSTAL FORM THEREOF AND PREPARATION METHOD THEREFOR | June 2025 | February 2026 | Allow | 7 | 1 | 0 | No | No |
| 19004230 | PARA ACYL SUBSTITUTED DIAZACYCLOHEXENE DERIVATIVES | December 2024 | August 2025 | Abandon | 7 | 1 | 0 | No | No |
| 18802914 | CRYSTALLINE FORMS OF (E)-N-HYDROXY-3-(1-(PHENYLSULFONYL)INDOLIN-5-YL)ACRYLAMIDE | August 2024 | September 2024 | Allow | 2 | 0 | 0 | No | No |
| 18730722 | RESOLVIN ANALOGS COMPOUNDS, METHODS AND USES THEREOF | July 2024 | February 2025 | Allow | 7 | 0 | 0 | No | No |
| 18656012 | ORGANIC COMPOUND (OXIME) TO COMBAT CHEMICAL WARFARE AGENTS | May 2024 | July 2025 | Allow | 14 | 3 | 0 | No | No |
| 18628594 | METHODS OF TREATING NEUROLOGICAL DISORDERS | April 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18615563 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | March 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18443965 | SELECTIVE REDUCTION OF a,B-UNSATURATED KETONE USING ELECTRONICALLY WEAKLY COUPLED 4,4'-DIVINYLAZOARYLENEBRIDGED DIRUTHENIUM CATALYST BEARING TWO Ru(CO)(3- METHOXYPYRIDIN-2-OLATE)(PiPR3)2 MOIETIES | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18436836 | PROCESSES FOR PREPARING QUINOLINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS | February 2024 | April 2024 | Allow | 3 | 2 | 0 | Yes | No |
| 18433237 | ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF | February 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18429297 | COMPOUND FOR USE IN RETINAL DISEASES | January 2024 | August 2025 | Allow | 18 | 0 | 0 | No | No |
| 18411842 | IRE1 SMALL MOLECULE INHIBITORS | January 2024 | April 2025 | Allow | 15 | 2 | 0 | No | No |
| 18397454 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | December 2023 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18395388 | TRIAZOLE DERIVATIVE AND USE THEREOF | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18545056 | BIS DISELENIDE-BASED SCHIFF BASES AS DEUBIQUITINATION SIGNALING PATHWAY MODULATORS | December 2023 | April 2024 | Allow | 4 | 0 | 0 | No | No |
| 18536864 | 9-(4-NITROBENZYLIDENE)-4-(4-NITROPHENYL)-3-CYANO-2-METHOXY-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDINE AS AN ANTIMICROBIAL COMPOUND | December 2023 | February 2024 | Allow | 2 | 0 | 0 | No | No |
| 18526149 | SMALL MOLECULE MODULATORS OF IL-17 | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18526960 | METHODS OF TREATING NEUROLOGICAL DISORDERS | December 2023 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18506060 | PYRIDIN-2(1H)-ONE QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | November 2023 | December 2024 | Allow | 13 | 1 | 0 | No | No |
| 18387620 | PARA ACYL SUBSTITUTED DIAZACYCLOHEXENE DERIVATIVES | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18386675 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | November 2023 | March 2025 | Allow | 16 | 1 | 0 | No | No |
| 18383677 | 5-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18493441 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | October 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18382697 | 4-[(SUBSTITUTED 1H-BENZIMIDAZOL-2-YLSULFANYL)METHYL]-6-SUBSTITUTED-2H-CHROMEN-2-ONES AS LARVICIDAL AGENTS | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18379835 | BENZYLIDENE DERIVATIVES OF FENOBAM AS ANTI-INFLAMMATORY AGENTS | October 2023 | December 2023 | Allow | 2 | 0 | 0 | No | No |
| 18379715 | AGONISTS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPARa) AND METHODS OF USE | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18484653 | POLYMORPHS OF (2S,5R)-5-(2-CHLOROPHENYL)-1-(2'-METHOXY-[1,1'-BIPHENYL]-4-CARBONYL)PYRROLIDINE-2-CARBOXYLIC ACID AND PREPARATION PROCESSES THEREOF | October 2023 | March 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18484264 | METHODS OF MAKING DELMOPINOL AND SALTS THEREOF | October 2023 | October 2025 | Allow | 25 | 2 | 0 | No | Yes |
| 18482912 | BIFUNCTIONAL CHELATORS AND CONJUGATES | October 2023 | January 2024 | Allow | 4 | 1 | 0 | Yes | No |
| 18377741 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18481844 | BIFUNCTIONAL CHELATORS AND CONJUGATES | October 2023 | February 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18480929 | MACROCYCLIC COMPOUNDS AND USES THEREOF | October 2023 | January 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18376386 | 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-(4-((5-(QUINOLIN-2-YLMETHYLENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUND | October 2023 | November 2023 | Allow | 1 | 0 | 0 | No | No |
| 18375672 | OXOIMIDAZOLIDINE DERIVATIVES AS ANTI-TUBERCULAR AGENTS | October 2023 | February 2024 | Allow | 5 | 1 | 0 | No | No |
| 18284455 | 2,4-DIAMINOPYRIMIDINE OXIDE PREPARATION METHOD | September 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18471170 | CRYSTALLINE FORMS OF A CANNABINOID RECEPTOR TYPE 1 (CB1) MODULATOR AND METHODS OF USE AND PREPARATION THEREOF | September 2023 | October 2024 | Allow | 13 | 3 | 0 | No | No |
| 18369136 | 1,2-DIOXO-2,3-DIHYDRO-1H-PYRROLO[2,3-C]QUINOLINE-7-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18242924 | PYRIDO[4,3-B]INDOLE-7-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18242759 | PYRROLO[3,2-C][2,7]NAPHTHYRIDINE-2-CARBOXYLIC ACID COMPOUNDS AS CK2 INHIBITORS | September 2023 | November 2023 | Allow | 2 | 1 | 0 | No | No |
| 18461023 | COMPOUNDS AND METHODS OF TREATING RETINAL DEGENERATION | September 2023 | November 2024 | Allow | 14 | 2 | 0 | No | No |
| 18239563 | 1-CYCLOPROPYL-6-FLUORO-7-(4-(2-HYDROXY-3-(NAPHTHALEN-2-YLOXY)PROPYLPIPERAZIN-1-YL)-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | August 2023 | October 2023 | Allow | 2 | 0 | 0 | No | No |
| 18234538 | SUBSTITUTED 1,4-DIHYDROPYRIMIDINES AS ANTITUBERCULAR AGENTS | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18264986 | BENZAZEPINE COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | August 2023 | March 2026 | Allow | 31 | 1 | 0 | No | No |
| 18276304 | SUBSTITUTED ISOXAZOLINE DERIVATIVES | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18366338 | POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | August 2023 | July 2024 | Allow | 11 | 1 | 0 | No | No |
| 18276135 | A PROCESS FOR PREPARING ABEDITEROL AND INTERMEDIATES THEREOF | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18356977 | PROCESSES OF MAKING 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES | July 2023 | July 2024 | Allow | 12 | 1 | 0 | No | No |
| 18273502 | N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | July 2023 | March 2026 | Allow | 32 | 2 | 0 | No | No |
| 18272840 | METHOD FOR PREPARING 2-[2-(2-CHLOROTHIAZOL-5-YL)-2-OXO-ETHYL]SULFANYL-6-HYDROXY-3-METHYL-5-PHENYL-PYRIMIDIN-4-ONE | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18344267 | CRYSTALLINE SOLID FORMS OF SALTS OF N-{4-[(6,7-DIMETHOXYQUINOLIN-4-YL)OXY]PHENYL}-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, PROCESSES FOR MAKING, AND METHODS OF USE | June 2023 | October 2024 | Allow | 15 | 1 | 0 | No | No |
| 18214002 | Highly Purified Batches Of Pharmaceutical Grade Migalastat And Methods Of Producing The Same | June 2023 | December 2024 | Allow | 17 | 1 | 0 | No | No |
| 18339366 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | June 2023 | September 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18259052 | HISTONE DEACETYLASE INHIBITORS | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18268667 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | June 2023 | January 2026 | Allow | 31 | 1 | 0 | Yes | No |
| 18267946 | Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18336332 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | June 2023 | August 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18267551 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | June 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18267331 | A Substituted Tetrahydroisoquinoline Derivative As A D1 Positive Allosteric Modulator | June 2023 | February 2026 | Allow | 32 | 1 | 0 | No | No |
| 18209075 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | June 2023 | January 2026 | Allow | 32 | 1 | 0 | No | No |
| 18334325 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | June 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 18266567 | PROCESS FOR THE PREPARATION OF PYRAZOLE-OXADIAZEPINE | June 2023 | September 2025 | Allow | 27 | 0 | 0 | No | No |
| 18330623 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | June 2023 | March 2026 | Allow | 33 | 0 | 1 | No | No |
| 18039540 | MANUFACTURING PROCESS FOR PREPARING GADOTERIDOL | May 2023 | January 2024 | Allow | 7 | 1 | 0 | No | No |
| 18255118 | SALTS OF A HETEROCYCLIC COMPOUND AND CRYSTALLINE FORMS, PROCESSES FOR PREPARING, THERAPEUTIC USES, AND PHARMACEUTICAL COMPOSITIONS THEREOF | May 2023 | March 2026 | Abandon | 33 | 1 | 0 | No | No |
| 18254405 | ANTICHOLINERGIC AGENTS | May 2023 | December 2025 | Allow | 31 | 1 | 0 | No | No |
| 18320761 | BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT | May 2023 | June 2024 | Allow | 13 | 2 | 0 | No | No |
| 18319828 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18037665 | Process For The Preparation Of Prothioconazole And Intermediates Thereof | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18253298 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18312484 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | May 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 18142432 | LIQUID AND SOLID STATE LASER FROM 7H-PYRANO[2,3-B:4,5-B']DIQUINOLINE DERIVATIVES USING ENERGY TRANSFER MECHANISM | May 2023 | February 2024 | Allow | 9 | 0 | 1 | No | No |
| 18139653 | TREATMENT OF HER2 POSITIVE CANCERS | April 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18032842 | METHODS OF MAKING NICOTINIC ACID DERIVATIVES | April 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18032732 | Bioactive Benzocycloheptene Analogues From Himachalenes and its Applications | April 2023 | December 2025 | Allow | 32 | 1 | 0 | No | No |
| 18030723 | KINASE MODULATORS AND METHODS OF USE THEREOF | April 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18130121 | PPARG INVERSE AGONISTS AND USES THEREOF | April 2023 | August 2023 | Allow | 4 | 0 | 0 | No | No |
| 18129363 | COMPOUND | March 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18121667 | SELECTIVE ESTROGEN RECEPTOR DEGRADERS | March 2023 | January 2024 | Allow | 10 | 1 | 0 | No | No |
| 18044829 | NOVEL DIBENZOACRIDINIUM DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS | March 2023 | January 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18025747 | COMPOSITIONS AND METHODS FOR TREATING MUSCULAR DYSTROPHIES | March 2023 | January 2026 | Allow | 35 | 1 | 1 | No | No |
| 18025487 | SMALL MOLECULE INHIBITORS OF ENPP1 | March 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18116920 | ACRIDIN-9-ONE COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | May 2023 | Allow | 3 | 0 | 0 | No | No |
| 18023995 | THERAPEUTIC COMPOUNDS | February 2023 | October 2025 | Allow | 32 | 1 | 0 | No | No |
| 18041944 | IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | February 2023 | November 2025 | Allow | 33 | 1 | 0 | No | No |
| 18168711 | CRYSTALLINE FORM OF LNP023 | February 2023 | March 2025 | Allow | 25 | 3 | 0 | No | No |
| 18107127 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | February 2023 | May 2023 | Allow | 4 | 1 | 0 | No | No |
| 18166235 | CARBOXYLIC ACID OR CARBOXYLIC ACID ESTER COMPOUND HAVING FUSED-RING STRUCTURE, METHOD FOR PRODUCING THE SAME, AND USE OF COMPOUND | February 2023 | February 2026 | Allow | 36 | 2 | 0 | Yes | No |
| 18040555 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | February 2023 | October 2025 | Allow | 32 | 1 | 0 | No | No |
| 18040608 | PYRIMETHAMINE CRYSTAL FORM | February 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18017275 | A COMPOSITION AND METHOD FOR PREPARING N-PHENYLPYRAZOLE-1-CARBOXAMIDES | January 2023 | December 2025 | Allow | 35 | 1 | 1 | No | No |
| 17783816 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE | December 2022 | December 2025 | Allow | 42 | 1 | 0 | No | No |
| 18085134 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | December 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18002035 | THYROMIMETICS | December 2022 | January 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18081395 | HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18079019 | Nemonoxacin malate active pharmaceutical ingredient with low combination impurities, and a preparation method thereof | December 2022 | January 2024 | Allow | 13 | 2 | 0 | No | No |
| 18008715 | PROCESS FOR THE PREPARATION OF FLUOXASTROBIN AND INTERMEDIATES THEREOF | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18062363 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | December 2022 | November 2023 | Allow | 12 | 1 | 0 | No | No |
| 18061745 | POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS | December 2022 | May 2023 | Allow | 5 | 0 | 0 | No | No |
| 17992399 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | November 2022 | October 2023 | Allow | 11 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SEAMAN, D MARGARET M.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 56.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SEAMAN, D MARGARET M works in Art Unit 1625 and has examined 1,952 patent applications in our dataset. With an allowance rate of 78.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner SEAMAN, D MARGARET M's allowance rate of 78.9% places them in the 48% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SEAMAN, D MARGARET M receive 1.29 office actions before reaching final disposition. This places the examiner in the 18% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SEAMAN, D MARGARET M is 22 months. This places the examiner in the 88% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a -9.3% benefit to allowance rate for applications examined by SEAMAN, D MARGARET M. This interview benefit is in the 3% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 41.8% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 81.0% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.0% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 44.3% are granted (fully or in part). This grant rate is in the 37% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 7.7% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.